Blood test spots multiple cancers without clea... - CLL Support

CLL Support

22,725 members38,985 posts

Blood test spots multiple cancers without clear symptoms, study finds

zaax profile image
zaax
2 Replies

theguardian.com/science/202...

web.archive.org/web/2022091...

Doctors have told health services to prepare for a new era of cancer screening after a study found a simple blood test could spot multiple cancer types in patients before they develop clear symptoms.

The Pathfinder study offered the blood test to more than 6,600 adults aged 50 and over, and detected dozens of new cases of disease. Many cancers were at an early stage and nearly three-quarters were forms not routinely screened for.

It is the first time results from the Galleri test, which looks for cancer DNA in the blood, have been returned to patients and their doctors, to guide cancer investigations and any necessary treatment.

The Galleri test has been described as a potential “gamechanger” by NHS England, which is due to report results from a major trial involving 165,000 people next year. Doctors hope the test will save lives by detecting cancer early enough for surgery and treatment to be more effective, but the technology is still in development.

“I think what’s exciting about this new paradigm and concept is that many of these were cancers for which we do not have any standard screening,” Dr Deb Schrag, a senior researcher on the study at the Memorial Sloan Kettering Cancer Center in New York, told the European Society for Medical Oncology meeting in Paris on Sunday.

In the Pathfinder study, 6,621 adults aged 50 and over were offered the Galleri blood test. For 6,529 volunteers, the test was negative, but it flagged a potential cancer in 92.

Further tests confirmed solid tumours or blood cancer in 35 people, or 1.4% of the study group. The test spotted two cancers in a woman who had breast and endometrial tumours.

Beyond spotting the presence of disease, the test predicts where the cancer is, allowing doctors to fast-track the follow-up work needed to locate and confirm a cancer. “The signal of origin was very helpful in directing the type of work-up,” said Schrag. “When the blood test was positive, it typically took under three months to get the work-ups completed.”

The test identified 19 solid tumours in tissues such as the breast, liver, lung and colon, but it also spotted ovarian and pancreatic cancers, which are typically detected at a late stage and have poor survival rates.

The remaining cases were blood cancers. Out of the 36 cancers detected in total, 14 were early stage and 26 were forms of the disease not routinely screened for.

Further analyses found the blood test was negative for 99.1% of those who were cancer-free, meaning only a small proportion of healthy people wrongly received a positive result. About 38% of those who had a positive test turned out to have cancer.

Schrag said the test was not yet ready for population-wide screening and that people must continue with standard cancer screening while the technology is improved. “But this still suggests a glimpse of what the future may hold with a really very different approach to cancer screening,” she said.

Fabrice André, the director of research at Gustave Roussy cancer centre in Villejuif, France, said: “Within the next five years, we will need more doctors, surgeons and nurses, together with more diagnostic and treatment infrastructure, to care for the rising number of people who will be identified by multi-cancer early detection tests.”

Naser Turabi, the director of evidence and implementation at Cancer Research UK, said: “Blood tests for multiple types of cancer used to belong in the realm of science fiction, but now they are an area of cancer research that is showing promise for patients.

“Research like this is crucial for making progress against late-stage cancers and giving more patients the chance of a good outcome. The Pathfinder trial results give us a better understanding of how frequently cancer is found by this blood test in people who haven’t been previously diagnosed.

“But we will need data from larger studies to fully assess this test and other similar tests in development, especially to understand whether people actually survive for longer after their cancer is picked up.”

Written by
zaax profile image
zaax
To view profiles and participate in discussions please or .
Read more about...
2 Replies
Fran57 profile image
Fran57

Amazing! What fantastic, encouraging research.

Thanks so much for this.

Stay safe,

Fran 😷

lexie profile image
lexie

This is very exciting for those of us who welcome knowing in advance. I have a number of friends without any apparent health issues who would rather not know. I was offered the Tempus genomic testing by my CLL specialist, which I agreed to without hesitation and would be open to this Galleri testing if offered.

You may also like...

Fake scientific papers push research credibility to crisis point

to develop protocols that researchers could apply to reveal the authenticity of studies that they...

Richter Transformation Survival in CLL Appears Better Among Treatment-Naive

overall survival among patients with CLL and RT was 3.1 years. Those patients who were previously...

New Dana Farber Research

cause the multiplication of CLL cancer cells. In a small trial of only 16 CLL patients who had...

Poole Conference 14 March 2024

Forconi took to the stage and his explanation of how things were developing were very interesting....

Diagnosed with Monoclonal B-cell lymphocytosis (MBL) and scared!

2017 my Lymph’s were at 2,900k. Doctor is screening me every 6months as if I was CLL stage 0! I...